Status:

TERMINATED

Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia

Lead Sponsor:

Sanofi

Conditions:

Hypercholesterolemia

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The present study is assessing the efficacy and safety of AVE5530 (25 mg and 50 mg) in add-on to ongoing statin treatment in a double-blind manner in comparison with placebo, in the management of pati...

Detailed Description

The two doses of AVE5530 tested in this study are 25 mg and 50 mg taken in the evening, with dinner dosing. The study will include a screening phase up to 2 weeks, a double-blind treatment period of a...

Eligibility Criteria

Inclusion

  • Adults with cholesterol levels not controlled on ongoing stable statin treatment

Exclusion

  • LDL-C levels \> 250 mg/dL (6.48 mmol/L)
  • Triglycerides \>350 mg/dL (3.95 mmol/L)
  • Conditions / situations such as:
  • presence of any clinically significant uncontrolled endocrine disease known to influence lipids levels
  • Active liver disease
  • Recent history of congestive heart failure , of unstable angina pectoris, myocardial infarction, coronary bypass surgery or angioplasty, or Unstable or severe peripheral artery disease
  • Positive test for Hepatitis B surface antigen and/or Hepatitis C antibody or Known to be Human Immunodeficient Virus (HIV) positive
  • Pregnant or breast-feeding women,
  • Women of childbearing potential not protected by effective contraceptive method of birth control (including oral contraceptives) and/or who are unwilling or unable to be tested for pregnancy prior to exposure to the Investigational Product
  • The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Key Trial Info

Start Date :

July 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2009

Estimated Enrollment :

1015 Patients enrolled

Trial Details

Trial ID

NCT00729027

Start Date

July 1 2008

End Date

June 1 2009

Last Update

May 16 2016

Active Locations (16)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (16 locations)

1

Sanofi-Aventis Administrative Office

Bridgewater, New Jersey, United States, 08807

2

sanofi-aventis Australia & New Zealand administrative office

Macquarie Park, New South Wales, Australia

3

Sanofi-Aventis Administrative Office

Diegem, Belgium

4

Sanofi-Aventis Administrative Office

Laval, Canada